HRS-9531

Kailera Therapeutics has appointed Jamie Coleman, former Eli Lilly Vice President and Zepbound® Brand Leader, as Chief Commercial Officer to spearhead commercialization strategy for their obesity drug pipeline.

Kailera Therapeutics' HRS9531, a dual GLP-1/GIP receptor agonist, demonstrated a 21.1% placebo-adjusted weight reduction in Phase II trials over 36 weeks.

Hengrui Pharmaceuticals and Kailera Therapeutics reported positive Phase 2 results for HRS9531, a GLP-1/GIP receptor dual agonist, in overweight or obese adults.

Four oral GLP-1 receptor (GLP-1R) agonists are in Phase III trials, signaling a shift in obesity treatment from injectables to more convenient oral options.

Kailera Therapeutics emerges with $400 million in Series A funding to develop next-generation GLP-1 therapies for obesity and related metabolic conditions.